摘要
食管癌确诊时中晚期患者居多,一旦疾病进展至晚期阶段,预后极差,既往传统方案化疗的患者中位总生存期不足一年。免疫检查点抑制剂治疗为食管癌患者带来新的契机,改变了既往治疗格局,目前化疗联合免疫治疗(PD-1抑制剂)已成为晚期食管癌的标准一线治疗,即便如此,晚期患者的中位总生存期也仅能达到12.4~17.2个月,仍不足以满足临床需求。在系统性治疗基础上联合局部治疗,寻求新的综合治疗模式是提高晚期食管癌疗效的重要研究方向。本文现就放疗在晚期食管癌中的研究进展和前景予以综述。
Esophageal cancer is predominantly diagnosed at a locally advanced or distant metastasis stage in patients.Once the disease progresses to the advanced stage,its prognosis is poor,and the median overall survival time of patients receiving traditional chemotherapy is less than one year.Treatment with immune checkpoint inhibitors has provided new opportunities to patients with esophageal cancer and changed the previous treatment pattern.Chemotherapy combined with immunotherapy(PD-1 inhibitor)has become the standard first-line treatment for advanced esophageal cancer.However,chemotherapy combined with immunotherapy have been reported a median overall survival time of only 12.4-17.2 months for patients.Such a survival time remains insufficient to meet clinical needs.Combining systemic treatment with local treatment and seeking new comprehensive treatment models are important research directions for improving efficacy.This article reviews the research progress and prospects of radiotherapy in the treatment of advanced esophageal cancer.
作者
王澜
WANG Lan(Department of Radiation Oncology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)
出处
《肿瘤防治研究》
CAS
2024年第6期397-401,共5页
Cancer Research on Prevention and Treatment
基金
河北省适用医学跟踪项目(GZ2024076)。
关键词
晚期食管癌
免疫治疗
放疗
Advanced esophageal cancer
Immunotherapy
Radiotherapy
